Compare Merck & Co., Inc. (MRK) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Stanley Black & Decker, Inc. — how do they compare? Merck & Co., Inc. trades at $148 (market cap $366.28B), while Stanley Black & Decker, Inc. trades at $91.6 (market cap $14.17B). The key difference: Merck & Co., Inc. is far larger — about 25.8× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.58%). Which is the better fit depends on your goals.
| MRK | SWK | |
|---|---|---|
Market Cap | $366.28B | $14.17B |
Sector | Health | — |
52-Week High | $156.43 | $104.00 |
52-Week Low | $77.60 | $62.12 |
Enterprise Value | $413.04B | $18.33B |
Dividend Yield | 2.29% | 3.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Stanley Black & Decker (SWK) trades at $93.81, down 3.65% on the day, with a bearish technical signal from moving averages and oscillators. The company reported three consecutive quarterly earnings beats, with Q3 2026 results pending. Recent portfolio refinement includes the sale of Excel Industries to Bad Boy Mowers. Valuation metrics show a P/E of 22.94 and P/S of 0.93, with a net income margin of 4.07% for 2025.
The outlook is mixed: analyst consensus is a $98.50 price target with 43% buy ratings, but technical indicators suggest near-term pressure. Opportunities include cost transformation benefits and dividend stability, while risks involve debt levels and industrial demand volatility. The stock's current price is near the low end of analyst targets, indicating potential upside if fundamentals strengthen.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
